Ferric Carboxymaltose Prevents Recurrence of Anemia in Patients With Inflammatory Bowel Disease

Evstatiev, Rayko; Alexeeva, Olga; Bokemeyer, Bernd; Chopey, Ivan V; Felder, Marcel; Gudehus, Maja; Iqbal, Tariq; Халиф, И. Л.; Marteau, Philippe; Stein, Jürgen M.; Gasché, Christoph

doi:10.1016/j.cgh.2012.10.013

Cited by 90 publications

(84 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evstatiev and colleagues performed another multicenter trial to evaluate the time to recurrence of anemia in patients with IBD within an 8-month study period [Evstatiev et al 2013]. Anemia recurred in 26.7% of subjects given FCM and in 39.4% given placebo.…”

Section: Ferric Carboxymaltosementioning

confidence: 99%

The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease

Koduru

Abraham

2015

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Iron deficiency anemia (IDA) is the most common form of nutritional anemia worldwide. Iron plays a pivotal role in vital functioning of almost every organ system. IDA affects both physical and psychological functioning of humans. Oral iron is considered as first-line therapy for the treatment of IDA due to low cost, good safety profile and ease of administration. However, the absorption of oral iron is affected by several factors and incidence of gastrointestinal side effects can lead to lack of adherence to therapy as well as poor efficacy. This has led to the emergence of intravenous iron therapy which is clearly superior to oral iron with higher increment of hemoglobin levels and rapid replenishment of iron stores. Ferric carboxymaltose (FCM) is a novel non-dextran intravenous iron form which has been approved for use in patients with iron deficiency who have had inadequate response to oral iron therapy, intolerance to oral iron, or nondialysis-dependent chronic kidney disease. The safety and efficacy of using FCM for the treatment of IDA has been demonstrated in several clinical trials. One dose can provide a large amount of iron and has a very short infusion time. It should be considered as first-line therapy in patients with active inflammation like inflammatory bowel disease when gastrointestinal absorption of oral iron may be compromised. It should also be given to patients who have inadequate response to oral iron therapy. It has been shown to be noninferior to other intravenous iron formulations with a good safety profile and produced fewer anaphylactic reactions.

show abstract

Section: Ferric Carboxymaltosementioning

confidence: 99%

The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease

Koduru

Abraham

2015

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Они более эффективны, безопасны и хорошо переносятся как для коррекции ЖДА, так и для поддержания запасов железа [26,27]. Основными препа-ратами железа для внутривенного введения считаются железа сахарат, железа карбоксимальтозат, железа гидрок-сид декстран, железа изомальтозат [28].…”

Section: лечение анемииunclassified

Features of the anemia at patients with Crohn’s disease

Ахмедов¹,

Иванюк²,

Бикбавова³

et al. 2018

Med. sov.

View full text Add to dashboard Cite

“…Recurrence of IDA is directly related with iron replenishment at the end of IV iron treatment [5,[44][45][46]. It is admitted that ferritin levels over 400 μg/L might prevent recurrence of IDA in the subsequent 1-5 years.…”

Section: Preventionmentioning

confidence: 99%

“…The recurrence of IDA in IBD is well recognized, occurring in about 50% of the adult patients within 10 months after IV iron treatment [5,7,44,45].…”

Section: Preventionmentioning

confidence: 99%

Anemia and IBD: Current Status and Future Prospectives

Lopes¹,

Azevedo²

2018

Current Topics in Anemia

View full text Add to dashboard Cite

Anemia is a common complication of inflammatory bowel disease (IBD), usually recognized at diagnosis and during flare-ups. However, the exact prevalence of anemia associated to IBD (IBD-A) is unknown. Despite its major clinical relevance and quality of life impact in both adult and pediatric IBD patients, it has been for long time neglected. It is mostly multifactorial, being a unique example of the combination of chronic iron deficiency (ID) and anemia of chronic disease (ACD). The current management of IBD-A represents a paradigm shift in clinical practice, involving several challenges. A pro-active approach is recommended and with the new generation of available iron compounds and recent guidelines, the ultimate goal will be the improvement of the patients' quality of life. Sound data are still lacking, concerning the best treatment/ prevention approach for IDA/ID. Based on current evidence, oral iron therapy might be preferred in mild IDA, whereas intravenous iron may be advantageous in more severe IDA/flaring IBD. Long-term prospective clinical trials are needed, to optimize treatment schedule and to better define the clinical and hematological long-term outcomes, both in adults and in children. They should demonstrate the efficacy, safety, and tolerance profile of different available iron formulas, as well as their cost-efficacy ratio.

show abstract

Ferric Carboxymaltose Prevents Recurrence of Anemia in Patients With Inflammatory Bowel Disease

Cited by 90 publications

References 26 publications

The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease

The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease

Features of the anemia at patients with Crohn’s disease

Anemia and IBD: Current Status and Future Prospectives

Contact Info

Product

Resources

About